RT Journal Article
SR Electronic
T1 Naloxone without transfusion prolongs survival and enhances cardiovascular function in hypovolemic shock.
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 621
OP 624
VO 220
IS 3
A1 N J Gurll
A1 D G Reynolds
A1 T Vargish
A1 R Lechner
YR 1982
UL http://jpet.aspetjournals.org/content/220/3/621.abstract
AB The hypothesis that opiate receptors are involved in the cardiovascular pathophysiology of hypovolemic shock was tested by using the opiate receptor antagonist naloxone. Naloxone increased mean arterial pressure, cardiac output, stroke volume and left ventricular dP/dtmax in a canine hemorrhagic shock model. Naloxone treatment also prolonged survival time. All these responses were dose-dependent and were independent of blood reinfusion. It is concluded that endorphins activated by stress act on opiate receptors to bring about some of the cardiovascular abnormalities in hypovolemic shock.